Menu

SCOPE-DMD

 

The main goal of the FP7 funded SCOPE-DMD project is to further advance and accelerate the development of PRO045, an exon-skipping compound for DMD. PRO045 is currently in a Phase IIb dose-escalating clinical trial to assess its safety and efficacy. The chemically-modified AON induces exon 45 skipping in the dystrophin gene and could be suitable for approximately 8% of all DMD patients.

SCOPE-DMD
Project started June 2013 and will end May 2016

Funded by FP7

Coordinated by

Volker Straub, Institute of Genetic Medicine, Newcastle University, UK




Menu